Investigator Initiated Trial Protocol Development Unit
Request help from the IIT PDU using the online project request form.
The purpose of the IIT PDU is to identify and promote high quality therapeutic-intent IITs and assist with study development utilizing regulatory, protocol writing, statistical, and clinical research associate expertise. The IIT PDU staff consists of a senior clinical research associate, a clinical research nurse, a regulatory associate, an OnCore information technology specialist, and a member of the Biostatistics Shared Resource Facility. Investigators may request IIT PDU support directly or be referred by their CCART, research program leaders, the Protocol Review and Monitoring Committee (PRMC), or the MCC Director. The intent of IIT PDU support is always to improve the likelihood of success and meaningful discovery.
Dr. Arnold, the Associate Director for Clinical Translation at MCC, has major research interests in lung cancer, head and neck cancer, experimental therapeutics and population-based cancer research. She has written and conducted over 10 original clinical trials in lung and head and neck cancer and has participated in numerous cooperative group trials. Dr. Arnold has also authored multiple investigator-initiated clinical trials in lung cancer. Her current research portfolio includes a large research grant from the Department of Defense grant to study the relationship of trace elements to lung cancer in Appalachian Kentucky.
Bryan Courtney, BS, CCRP, Director of Clinical Research Operations
Mr. Courtney has 16 years of experience in the health care industry and nine years in clinical cancer research. Before becoming the Associate Administrative Director for the clinical cancer research unit at Mayo Clinic (Florida), he was the lead CRA for neuro-oncology, GI, melanoma, and sarcoma studies. He is a national auditor for SWOG. Mr. Courtney manages all daily operation of the CRDM SRF, and under his leadership, new policies and procedures have been implemented to ensure operational efficiency in support of quality clinical cancer trials.